News & Updates

Can a cancer drug be repurposed for allergic reactions?

22 Mar 2023 by

A small but promising study showed that acalabrutinib, an oral BTK* inhibitor approved for B-cell malignancies**, may reduce or even prevent clinical reactivity to peanuts in peanut-allergic adults.

Can a cancer drug be repurposed for allergic reactions?

22 Mar 2023

Efficacy of Bivalent Boosters Against Severe Omicron

22 Mar 2023

Bivalent boosters provide substantial additional protection against severe COVID-19 caused by the Omicron variant. On August 31, 2022, the US Food and Drug Administration (FDA) approved bivalent COVID-19 vaccines for use as a single booster dose.

Efficacy of Bivalent Boosters Against Severe Omicron

22 Mar 2023

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure

21 Mar 2023

Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure

21 Mar 2023

Menopausal hormone therapy use carries increased T2DM risk

21 Mar 2023

The use of menopausal hormone therapy (MHT), including the most prescribed agent tibolone, appears to contribute to an increase in the risk of type 2 diabetes mellitus (T2DM), as shown in a retrospective study.

Menopausal hormone therapy use carries increased T2DM risk

21 Mar 2023

Neurologic disability predicts severe ED in men infected with HTLV-1

21 Mar 2023

Patients with human T-lymphotropic virus 1 (HTLV-1) infection may develop erectile dysfunction (ED), and time to progression to its severe form is significantly associated with the degree of neurologic compromise at baseline, reveals a study.

Neurologic disability predicts severe ED in men infected with HTLV-1

21 Mar 2023

Neurocognitive impairment plagues older PLHIV

21 Mar 2023 by

Healthcare providers and other care partners need greater awareness and training on neurocognitive impairment, mental health, and comorbidities that afflict older people living with HIV (PLHIV), suggests a Singapore study.

Neurocognitive impairment plagues older PLHIV

21 Mar 2023

CBT, mindfulness help improve sexual outcomes in prostate cancer

21 Mar 2023

Mindfulness and cognitive behavioural therapy (CBT) appear beneficial for prostate cancer survivors and their partners who are dealing with sexual dysfunction, a study has shown.

CBT, mindfulness help improve sexual outcomes in prostate cancer

21 Mar 2023

New data support B/FTC/TAF use in HIV+ children

21 Mar 2023 by

Data from a French study presented at CROI 2023 support the use of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/FTC/TAF) in the management of paediatric patients with HIV.

New data support B/FTC/TAF use in HIV+ children

21 Mar 2023

Rifaximin helps improve symptoms of IBS with diarrhoea

21 Mar 2023

Treatment with rifaximin appears to produce significant reductions in multiple, concurrent symptoms of irritable bowel syndrome (IBS) with diarrhoea, according to a study that uses a novel tri-symptom endpoint.

Rifaximin helps improve symptoms of IBS with diarrhoea

21 Mar 2023

Bempedoic acid cuts CV events in statin-intolerant patients

21 Mar 2023 by

The use of bempedoic acid significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with high cholesterol who are intolerant to statins in the phase III CLEAR* Outcomes trial presented at ACC.23/WCC.

Bempedoic acid cuts CV events in statin-intolerant patients

21 Mar 2023

News & Updates

Filter by Specialty:

Specialty:

Can a cancer drug be repurposed for allergic reactions?

Can a cancer drug be repurposed for allergic reactions?

Efficacy of Bivalent Boosters Against Severe Omicron

Efficacy of Bivalent Boosters Against Severe Omicron

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure

Menopausal hormone therapy use carries increased T2DM risk

Menopausal hormone therapy use carries increased T2DM risk

Neurologic disability predicts severe ED in men infected with HTLV-1

Neurologic disability predicts severe ED in men infected with HTLV-1

Neurocognitive impairment plagues older PLHIV

Neurocognitive impairment plagues older PLHIV

CBT, mindfulness help improve sexual outcomes in prostate cancer

CBT, mindfulness help improve sexual outcomes in prostate cancer

New data support B/FTC/TAF use in HIV+ children

New data support B/FTC/TAF use in HIV+ children

Rifaximin helps improve symptoms of IBS with diarrhoea

Rifaximin helps improve symptoms of IBS with diarrhoea

Bempedoic acid cuts CV events in statin-intolerant patients

Bempedoic acid cuts CV events in statin-intolerant patients